🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

FLNA FLNA

Company Profile ↓
$0.96
-58.09% 1Y
P/E-0.51
52W High$4.64
52W Low$0.87
EPS (TTM)$-1.88

Company Overview

FLNA (FLNA) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 18.9% CAGR over the past five years.

Recent Developments

  • Trailing 12 Months Year-on-year growth — revenue +277.6%.
  • 5-Year Trend Long-term compounding — revenue CAGR 18.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:18.92%
1 Year:277.58%

Stock Price Performance

1 Year:-58.09%
6 Months:-51.28%
3 Months:-30.45%
1 Month:-26.73%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 2% of range
$0.87 $4.64
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)39.71 · Neutral
Price Performance
1M-26.73%
3M-30.45%
6M-51.28%
1Y-58.09%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 18.9% over 5 years.

CONS

  • Trading 79.3% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-0.51
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$-
Price to Book
-
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
18.92%
Profit 5Y
-
Revenue (YoY)
277.58%
Earnings (YoY)
-

Profitability & Returns

ROCE
-128.00%
ROE
-122.27%
ROA
-76.86%
Profit Margin
-
Op Margin
-
Gross Margin
-
EPS (Latest Qtr)
$-0.22
EPS (TTM)
$-1.88

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
-
Current Ratio
-
Debt
-
Total Assets
$108.37M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
2.05%
Chg in Prom Hold
-
FII / Inst Holding
28.58%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$41.12M
EBITDA
-
Free Cash Flow
$-32.83M
Operating Cash Flow
$-32.25M
Shares Outstanding
-
Gross Margin
-
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2014Jun 2014Sep 2014Dec 2014Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Operating Income -3.46M-3.26M-3.54M--2.60M-3.39M-3.69M--5.83M-3.04M-3.54M--2.76M-4.17M-2.60M-2.17M-2.46M-1.28M-1.45M-1.15M-779.00K-1.22M-1.16M-1.44M-3.53M-5.14M-9.75M-17.82M-19.92M-21.34M-26.51M-28.78M-27.88M-19.93M-61.40M-30.62M-24.59M-45.39M-11.86M-11.17M
Net Income -3.45M-3.25M-3.53M-2.16M-2.58M-3.37M-3.67M-4.52M-5.79M-3.02M-3.52M-2.52M-2.74M-4.16M-2.59M-2.16M-2.45M-1.27M-1.36M-1.06M-697.00K-1.15M-1.14M-1.43M-3.53M-5.12M-9.56M-17.53M-19.33M-20.26M-24.27M-26.38M-25.65M25.04M6.16M-27.94M-23.40M-44.22M-10.81M-10.33M
Diluted EPS ----------------------------0.44-0.48--0.58-0.63-0.61-0.430.13-0.58-0.48-0.92-0.22-
R&D Expense 2.15M1.94M2.12M-1.14M1.99M2.36M-3.60M1.59M2.66M-1.39M3.06M1.62M1.07M1.46M1.46M574.00K308.00K---------18.53M22.12M24.97M23.60M16.23M15.20M17.68M13.67M5.12M3.96M4.54M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 20.56M16.81M11.48M10.89M41.12M------------
Operating Income -6.75M-13.70M-3.51M-3.90M31.36M-12.43M-14.20M-14.96M-11.95M-6.66M-4.96M-6.45M-32.87M-80.02M-105.96M-141.45M-95.39M
Net Income -3.47M-12.02M-2.61M-3.45M31.54M-12.39M-14.14M-14.85M-11.91M-6.56M-4.63M-6.33M-32.38M-76.25M-97.22M-24.34M-90.97M
Diluted EPS ---0.06-0.080.70-0.27-0.31-------1.90-2.32-1.46-1.88
R&D Expense 21.06M15.75M8.30M7.61M4.92M7.31M9.10M9.18M7.62M2.97M--24.81M68.03M89.42M69.64M26.59M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --99.19M98.96M56.86M50.10M40.91M31.92M19.30M10.83M20.14M23.49M94.30M266.78M234.83M151.66M157.53M118.36M
Total Equity 104.29M108.25M32.93M44.39M13.14M48.30M40.06M29.37M18.64M9.70M19.63M22.10M92.20M253.91M227.54M137.47M145.70M74.40M
Cash & Equivalents 153.16M35.79M4.80M73.14M49.35M48.59M40.59M31.30M16.61M10.48M19.81M23.08M93.51M233.44M201.01M121.14M128.57M95.50M
Total Liabilities --66.26M54.57M43.72M1.80M850.00K2.55M665.00K1.13M511.00K1.39M2.10M12.87M7.29M14.20M11.83M43.95M
Current Liabilities --14.07M13.27M10.00M1.80M850.00K2.55M665.00K1.13M511.00K1.39M1.86M12.53M7.06M14.20M11.75M43.83M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -14.69M-143.00K-260.00K-7.17M---12.23M-8.24M-4.77M-2.51M-5.38M-30.20M-77.51M-82.03M-116.93M-32.25M
Investing Cash Flow -103.23M52.46M59.90M17.62M---2.17M2.10M--18.00K360.00K-22.21M-2.71M-414.00K-103.00K-581.00K
Financing Cash Flow 555.00K-83.32M8.70M-34.24M---284.00K-14.10M5.81M75.45M192.34M47.80M2.56M124.47M-239.00K
Capital Expenditure -----80.00K-195.00K-75.00K---18.00K--22.21M-2.71M-414.00K-103.00K-581.00K
Free Cash Flow -------12.31M---2.53M--52.41M-80.23M-82.44M-117.03M-32.83M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -----------------
Operating Margin % -32.8%-81.5%-30.6%-35.8%76.3%------------
Net Margin % -16.9%-71.5%-22.8%-31.6%76.7%------------
ROE % -3.2%-36.5%-5.9%-26.2%65.3%-30.9%-48.2%-79.7%-122.8%-33.4%-21.0%-6.9%-12.8%-33.5%-70.7%-16.7%-122.3%
ROCE % --16.1%-4.1%-8.3%64.9%-31.0%-48.4%-80.3%-123.2%-33.9%-22.4%-7.0%-12.9%-35.1%-77.1%-97.0%-128.0%

Shareholding Pattern

Insiders
2.05%
Institutions
28.58%
Public Float
29.18%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for FLNA

Yahoo Finance Wed, 29 Jul 2026

Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update

AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related …

Yahoo Finance hu, 07 May 2026

Filana Therapeutics Reports Q1 2026 Financial Results and Business Update

AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related e…

Yahoo Finance Fri, 29 May 2026

Data I/O And 2 Other Promising Penny Stocks To Watch

The United States market has seen a robust performance recently, climbing 1.8% in the last 7 days and up 28% over the past year, with earnings forecasted to grow by 17% annually. For investors seeking opportunities beyond well-known large-c…

Yahoo Finance ue, 05 May 2026

Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII

Presentation described the biological rationale for the evaluation of simufilam in TSC-related epilepsyAUSTIN, Texas, May 05, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotech…

Yahoo Finance Wed, 15 Apr 2026

Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data

Study in a well-accepted mouse model of severe Tuberous Sclerosis Complex (TSC) showed that simufilam attenuated the progression of seizures in a dose-dependent mannerResults confirm and extend previously published preclinical findingsTSC-r…

FLNA — Frequently Asked Questions

What is the current share price of FLNA?

As of 2026-08-05 17:25 PDT, FLNA trades at $0.96 on NASDAQ/NYSE. Its 52-week range is $0.87 to $4.64.

What is the P/E ratio of FLNA?

FLNA trades at a trailing price-to-earnings (P/E) ratio of -0.51.

What is the return on equity (ROE) of FLNA?

FLNA has a return on equity (ROE) of -122.27%. Its return on capital employed (ROCE) is -128.00%.

Is FLNA a good stock to buy?

This page provides a data-driven analysis of FLNA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space